Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.
Bruna Mascaro-CordeiroIndhira Dias OliveiraFrancine Tesser-GambaLorena Favaro PavonNasjla Saba-SilvaSergio CavalheiroPatrícia DastoliSilvia Regina Caminada ToledoPublished in: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2018)
MB tumors belonging to SHH molecular subgroup, with TP53MUT, would be the ones that present high risk in relation to VA use during the treatment, while TP53WT MBs can benefit from VA therapy, both SHH and groups 3 and 4. Our study shows a new perspective about VA action in medulloblastoma cells, raising the possibility that VA may act in different patterns. According to the genetic background of MB cell, VA can stimulate cell cycle arrest and apoptosis or induce resistance to treatment via signaling pathways activation.